A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers

K. Behbakht, L. S. Massad, E. L. Yordan, S. H. Lincoln, J. A.H. Eriksson, L. Winkelman, K. DeGeest, C. Kirschner, G. D. Wilbanks

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Persistent or recurrent squamous malignancies of the female genital tract are usually incurable by conventional therapy, and results of single agent chemotherapy have been disappointing. We undertook this study to confirm a previously reported response rate of 69%, using a regimen of bleomycin 30U, ifosfamide 5g/m2 with mesna 6g/m2, and cisplatin 50 mg/m2 (BIP) for recurrent cervical cancer. This regimen was used to treat persistent or recurrent squamous cancers in women with cervical cancer (n = 11), vaginal cancer (n = 1) and vulvar cancer (n = 1). Results were reviewed retrospectively and toxicities graded according to the criteria of the Gynecologic Oncology Group. No complete responses were seen. One patient had a partial response (10%, 95% confidence interval 0-28%). Five patients (50%), exhibiting stable disease during therapy with BIP, progressed after cessation of therapy. Of 9 women with symptoms after one cycle. Significant toxicities included neutropenic fever (3 grade 3, 3 grade 4), emesis (1 grade 3), confusion (2 grade 4), vaginal bleeding (2 grade 3), and renal failure (1 grade 3). Eight patients were transfused with a total of 28 units of red cells. After 23 months of follow-up, all patients were dead of disease. Mean survival was 10 months. Toxicity associated with this regimen can be significant, and results appear no better than those reported with single agent therapy.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalEuropean Journal of Gynaecological Oncology
Volume17
Issue number1
StatePublished - Feb 7 1996

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers'. Together they form a unique fingerprint.

  • Cite this

    Behbakht, K., Massad, L. S., Yordan, E. L., Lincoln, S. H., Eriksson, J. A. H., Winkelman, L., DeGeest, K., Kirschner, C., & Wilbanks, G. D. (1996). A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers. European Journal of Gynaecological Oncology, 17(1), 7-12.